Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen

Introduction: Tamoxifen dominates the anti-estrogenic therapy in the early and metastatic breast cancer setting. Tamoxifen has a complex metabolism, being mainly metabolized by CYP2D6 into its 30–100 times more potent metabolite, endoxifen. Recently, a phase I study in which endoxifen as an orally z-endoxifen hydrochloride has been successfully evaluated.

Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.

Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available.     

Predictive factors of positive online patient ratings of spine surgeons

BACKGROUND

Online physician rating websites are increasingly used by patients to evaluate their doctors. The purpose of this investigation was to evaluate factors associated with better spine surgeon ratings.

Multidisciplinary management of patients presenting with Lyme disease suspicion

Objective

The teaching hospital of Nancy, France, implemented a specific multidisciplinary care pathway (French acronym AMDPL) to improve the management of patients presenting with Lyme borreliosis (LB) suspicion. We aimed to assess the first year of activity of this care pathway.

Editorial Commentary: “Dancing the Hip Away”—Does Joint Laxity Correlate With Worse Outcome in Dancers Undergoing Hip Arthroscopy for Femoral Acetabular Impingement?

Dancers have a disproportionately high prevalence of hip issues compared with other types of athletes. Many of these hip issues are complex: a cam and/or pincer impingement combined with a seemingly paradoxical borderline dysplasia, capsular laxity, and subsequent instability. Our experience as nonarthritic hip surgeons tells us that careful patient selection is critical for a successful outcome after the arthroscopic treatment of a dancer. But, there is little guidance in the literature on the management of this specific group of patients. We have studies that advise us to repair the labrum when possible versus performing labral debridement in female patients with predominantly pincer-type impingement and studies that support capsular plication and careful capsule closure in patients, predominantly female patients, with combined hip impingement and dysplasia or borderline dysplasia. However, few studies have examined predictors of outcomes after hip arthroscopy in dancers.